Market capitalization | $9.19b |
Enterprise Value | $8.96b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.50 |
P/S ratio (TTM) P/S ratio | 3.59 |
P/B ratio (TTM) P/B ratio | 1.37 |
Revenue growth (TTM) Revenue growth | -7.46% |
Revenue (TTM) Revenue | $2.56b |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
9 Analysts have issued a Bio-Rad Laboratories, Inc. Class B forecast:
9 Analysts have issued a Bio-Rad Laboratories, Inc. Class B forecast:
Jun '24 |
+/-
%
|
||
Revenue | 2,563 2,563 |
7%
7%
|
|
Gross Profit | 1,384 1,384 |
8%
8%
|
|
EBITDA | 557 557 |
4%
4%
|
EBIT (Operating Income) EBIT | 361 361 |
6%
6%
|
Net Profit | -1,326 -1,326 |
208%
208%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
Head office | United States |
CEO | Norman Schwartz |
Employees | 8,030 |
Founded | 1952 |
Website | www.bio-rad.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.